ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Patients with chronic‐phase chronic myeloid leukemia (CP‐CML) resistant to a second‐generation (2G) BCR::ABL1 TKI experience low response rates and poor long‐term outcomes when treated with another 2G TKI.5, 6, 7